Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant
(SOT) recipients, either by direct injury or in association with chronic allograft rejection or …

We assessed valganciclovir for the treatment of cytomegalovirus (CMV) in organ-transplant
recipients. Virologic and clinical outcomes were compared with those in matched historical …

Valganciclovir (VGC) has proved efficacious and safe for the prophylaxis against
cytomegalovirus (CMV) in high-risk transplant recipients and for the treatment of CMV …

Recent data suggest valganciclovir (VGC) to be as effective as ganciclovir for
cytomegalovirus (CMV) prophylaxis. The objective of this study was to analyze the effect of …

The VICTOR study showed comparable efficacy of treatment with intravenous ganciclovir
and oral valganciclovir for cytomegalovirus (CMV) disease in solid organ transplant …

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …

We prospectively followed 70 CMV-seropositive solid organ transplant recipients to evaluate
the efficacy and safety of valganciclovir (VGCV) as preemptive therapy based on …

Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ
transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized …

Background In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus
(CMV) infection contributes significantly to morbidity and mortality in both the early and late …

Importance of the field: Cytomegalovirus (CMV) infection is the most common viral infectious
complication after solid organ transplantation (SOT). Ganciclovir is the first-line anti-CMV …